Study of immune response in digestive cancers
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This study collects tissue and blood samples from people with colorectal, pancreatic, or bile duct cancer to learn how the immune system reacts to these tumors. The goal is to better understand cancer biology and potentially improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with colorectal, pancreatic, or bile duct cancer.
- Your cancer diagnosis was confirmed by a biopsy or cytology test.
- You were diagnosed in 2015 or later.
- You are willing to provide consent and have health coverage (including state coverage like CMU).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how gut bacteria and immune activity differ in normal, pre-cancer, and cancer colon tissue. It may help researchers understand what changes in the body are linked to colon growth and how they could be targeted in the future.
This study looks at how bacteria in your gut, your immune system, and colon cancer interact. It aims to understand these connections to improve future treatments.
This study looks at how the immune system reacts to colorectal cancer in the body. It aims to understand immune responses better, which may help improve future treatments.
This study looks at how tumors in the digestive system interact with the body’s immune system and the surrounding environment. Results may help improve understanding of these cancers and guide future treatments.
This study looks at what makes some cancers more “noticeable” to the immune system. It may help researchers design better future immunotherapy by collecting information (often including blood samples) from people with different cancers.
This study collects clinical and lab information to better understand metastatic cancers of the digestive system and how patients respond to treatment. It may help improve future care, but it is mainly focused on collecting data rather than testing a new drug.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.